2026-526282-25-00RecruitingPhase 1
A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 15 Jun 2026
- Start date
- 17 Sept 2026
- Lead sponsor
- AbbVie Deutschland GmbH & Co. KG
- Diseases
- Lupus (SLE), Rheumatoid arthritis
- EU CT number
- 2026-526282-25-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Research Organisation GmbH | Berlin | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.